Abstract
Large scale toxicological testing programmes which are currently ongoing such as the new European chemical legislation REACH require the development of new integrated testing strategies rather than applying traditional testing schemes to thousands of chemicals. The current practice of requiring in vivo testing for every possible adverse effect endanger the success of these programmes due (i) to limited testing facilities and sufficient capacity of scientific/technical knowledge for reproductive toxicity; (ii) an unacceptable number of laboratory animals involved (iii) an intolerable number of chemicals classified as false positive. A key aspect of the implementation of new testing strategies is the determination of prevalence of reproductive toxicity in the universe of industrial chemicals. Prevalences are relevant in order to be aware on the expected rate of false classification during the toxicological testing and to implement appropriate measures for their avoidance. Furthermore, a detailed understanding on the subendpoints affected by reproductive toxicants and the underlying mechanisms will lead to more science based testing strategies integrating alternative methods without compromising the protection of consumers.
Keywords: REACH, reproductive toxicity, prevalence, alternative methods, validation, ReProTect
Current Pharmaceutical Design
Title: The Development of New Concepts for Assessing Reproductive Toxicity Applicable to Large Scale Toxicological Programmes
Volume: 13 Issue: 29
Author(s): S. Bremer, C. Pellizzer, S. Hoffmann, T. Seidle and T. Hartung
Affiliation:
Keywords: REACH, reproductive toxicity, prevalence, alternative methods, validation, ReProTect
Abstract: Large scale toxicological testing programmes which are currently ongoing such as the new European chemical legislation REACH require the development of new integrated testing strategies rather than applying traditional testing schemes to thousands of chemicals. The current practice of requiring in vivo testing for every possible adverse effect endanger the success of these programmes due (i) to limited testing facilities and sufficient capacity of scientific/technical knowledge for reproductive toxicity; (ii) an unacceptable number of laboratory animals involved (iii) an intolerable number of chemicals classified as false positive. A key aspect of the implementation of new testing strategies is the determination of prevalence of reproductive toxicity in the universe of industrial chemicals. Prevalences are relevant in order to be aware on the expected rate of false classification during the toxicological testing and to implement appropriate measures for their avoidance. Furthermore, a detailed understanding on the subendpoints affected by reproductive toxicants and the underlying mechanisms will lead to more science based testing strategies integrating alternative methods without compromising the protection of consumers.
Export Options
About this article
Cite this article as:
Bremer S., Pellizzer C., Hoffmann S., Seidle T. and Hartung T., The Development of New Concepts for Assessing Reproductive Toxicity Applicable to Large Scale Toxicological Programmes, Current Pharmaceutical Design 2007; 13 (29) . https://dx.doi.org/10.2174/138161207782110462
DOI https://dx.doi.org/10.2174/138161207782110462 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Updated Research and Applications of Small Molecule Inhibitors of Keap1-Nrf2 Protein-Protein Interaction: a Review
Current Medicinal Chemistry Illuminating microRNA Transcription from the Epigenome
Current Genomics Discovery and Pre-clinical Development of Antithrombotics from Hematophagous Invertebrates
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Susceptibility Genes in Hypertension
Current Pharmaceutical Design Mesenchymal Stem Cells as Mediators of Neural Differentiation
Current Stem Cell Research & Therapy Gender Disparity in Pediatric Diseases
Current Molecular Medicine Casein Phosphopeptides in Oral Health - Chemistry and Clinical Applications
Current Pharmaceutical Design Detection of a Left Atrial Thrombus Under Fondaparinux Treatment: A Case Report
Current Drug Safety Antithrombotic Therapy After TAVR
Current Vascular Pharmacology New Insight into Diabetes Management: From Glycemic Index to Dietary Insulin Index
Current Diabetes Reviews Determinants of the Resolution of Type 2 Diabetes After Bariatric Surgery
Vascular Disease Prevention (Discontinued) Gene Patents Related to Common Diseases of the Eye
Recent Patents on DNA & Gene Sequences Immune-Neuroendocrine Interactions Involving Thymus and Pineal Gland in Stem Cell Therapy of Age-Related Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Nephron Number Reduction and Low Birth Weight: A Concern for the Paediatrician and Beyond
Current Pediatric Reviews Evolutionary Advantage and Molecular Modes of Action of Multi-Component Mixtures Used in Phytomedicine
Current Drug Metabolism Nitric Oxide and Protection against Cardiac Ischemia
Current Pharmaceutical Design Third and Fourth Generation Fluoroquinolone Antibacterials: A Systematic Review of Safety and Toxicity Profiles
Current Drug Safety Parental Hypertension and Cardiovascular Reactivity in Young Adults
Vascular Disease Prevention (Discontinued) Cellular Iron Homeostasis and Therapeutic Implications of Iron Chelators in Cancer
Current Pharmaceutical Biotechnology Antiapoptotic Effect of Novel Compound from Herba leonuri-Leonurine (SCM-198): A Mechanism Through Inhibition of Mitochondria Dysfunction in H9c2 Cells
Current Pharmaceutical Biotechnology